AP NEWS

Poxel Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

September 4, 2018

LYON, France--(BUSINESS WIRE)--Sep 4, 2018--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the H.C. Wainwright 20 th Annual Global Investment Conference.

The H.C. Wainwright 20 th Annual Global Investment Conference is being held on September 4-6 th at The St. Regis Hotel in New York City. The Company will present a corporate overview on Thursday, September 6 th from 10:00-10:25 AM ET in Louis XVI A room on the 2nd floor and will be available to participate in one-on-one meetings with investors. The presentation at the H.C. Wainwright 20 th Annual Global Investment Conference will be webcast live. To access the webcast, please visit the following link http://wsw.com/webcast/rrshq28/poxel.pa/. The webcast replay will remain available for 90 days following the live presentation.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3  T rials of IM eglimin for  E fficacy and  S afety (TIMES) program for the treatment of type 2 diabetes in Japan.   Our partner   Roivant Sciences is responsible for Imeglimin’s development and commercialization in countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. DRX-065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC), is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL,  www.poxelpharma.com )

View source version on businesswire.com:https://www.businesswire.com/news/home/20180903005269/en/

CONTACT: Poxel SA

Jonae R. Barnes, +1 617 818 2985

Senior Vice President, Investor Relations and Public Relations

jonae.barnes@poxelpharma.com

or

Investor relations / Media - EU/US

Trophic Communications

Gretchen Schweitzer or Stephanie May

+49 89 238 877 34 or +49 171 185 56 82

may@trophic.eu

or

Investor relations / Media - France

NewCap

Alexia Faure/Nicolas Merigeau

+33 1 44 71 98 51

poxel@newcap.eu

KEYWORD: UNITED STATES EUROPE NORTH AMERICA FRANCE MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL COMMUNICATIONS PUBLIC RELATIONS/INVESTOR RELATIONS

SOURCE: POXEL S.A.

Copyright Business Wire 2018.

PUB: 09/04/2018 02:00 AM/DISC: 09/04/2018 02:01 AM

http://www.businesswire.com/news/home/20180903005269/en

AP RADIO
Update hourly